- Home
- CLB vs FULC Comparison
CLB vs FULC Comparison
Compare CLB & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLB | FULC |
|---|---|---|
| Founded | 1936 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 864.2M | 707.9M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CLB | FULC |
|---|---|---|
| Price | $18.61 | $9.77 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $12.50 | ★ $16.38 |
| AVG Volume (30 Days) | 370.2K | ★ 675.2K |
| Earning Date | 02-04-2026 | 02-24-2026 |
| Dividend Yield | ★ 0.22% | N/A |
| EPS Growth | ★ 2.46 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $526,520,000.00 | N/A |
| Revenue This Year | $3.64 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.45 | ★ N/A |
| Revenue Growth | 0.51 | ★ 2752.05 |
| 52 Week Low | $9.72 | $2.32 |
| 52 Week High | $20.36 | $15.74 |
Technical Indicators
Market Signals| Indicator | CLB | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 55.05 | 40.43 |
| Support Level | $16.98 | $9.52 |
| Resistance Level | $20.05 | $10.51 |
| Average True Range (ATR) | 0.82 | 0.67 |
| MACD | -0.15 | -0.09 |
| Stochastic Oscillator | 65.98 | 11.02 |
Price Performance
Historical ComparisonAbout CLB Core Laboratories Inc.
Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.